Simon Ategbo

Simon Ategbo

Auto-generated profile, based on publicly available information

Simon Ategbo

Service de Pédiatrie, Centre Hospitalier Universitaire Mère-Enfant Fondation Jeanne Ebori, Rue Pierre Barro, Libreville BP 2254, Gabon

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
Berthold BIVIGOU MBOUMBABerthold BIVIGOU MBOUMBA
Berthold BIVIGOU MBOUMBA
PBPamela Moussavou Boundzanga
Pamela Moussavou Boundzanga
FAFalone L. Akombi
Falone L. Akombi
CZCarine Eyi Zang
Carine Eyi Zang
ABAurore F. Bouassa-Bouassa
Aurore F. Bouassa-Bouassa
SASimon Ategbo
Simon Ategbo
Background: Children, adolescents and young adults living with HIV represent a vulnerable population. Achieving viral suppression in this population remains a major challenge in sub-Saharan Africa. Methods: We conducted a cross-sectional study among HIV-positive individuals aged 0–24 years in Gabon. Data were collected, including viral load (VL), CD4 counts, and immunosuppression levels. Viral suppression was defined as VL < 1000 copies/mL. Statistical comparisons across age groups and immunosuppression categories were performed. Results: Of the 130 (100%) participants included, 59 (45.4%) were males and 71 (54.6%) females. Overall, 72 (55.4%) achieved viral suppression, while 58 (44.6%) remained uncontrolled. Viral suppression increased with age (23.8% (5/21) in 0–7 years; 29.2% (14/48) in 8–15 year and 42.6% (26/61) in 16–24 years), yet uncontrolled VL were predominant across all groups. Median VL values were low but showed wide interquartile ranges, indicating heterogeneity in viral control. Mean CD4 counts declined significantly with age (780 in 0–8 years vs. 470 in 16–24 years; p = 0.001). Immunosuppression levels correlated inversely with virological control (p < 0.001). Conclusions: Despite moderate overall viral suppression, nearly half of adolescents and young adults failed to achieve virological control. The decline in CD4 counts with age highlights increased vulnerability in this population.

1 December 2022 in The Moldovan Medical Journal
Verified
Journal Article
Closed access
CVChiril Voloc
Chiril Voloc
ARAliona Rotari
Aliona Rotari
AVAlexandru Voloc
Alexandru Voloc
EKEliane Kuissi Kamgaing
Eliane Kuissi Kamgaing
JSJoel Fleury Djoba Siawaya
Joel Fleury Djoba Siawaya
SASimon Jonas Ategbo
Simon Jonas Ategbo
Background: Vitamin D plays an important role in the prevention of many diseases. More than 1 billion people worldwide suffer from vitamin D deficiency. Vitamin D deficiency can contribute to the development of 16 types of cancer (breast, colon, prostate, etc.), cardiovascular diseases, stroke, autoimmune diseases, periodontal pathologies, transplant failure in endo-alveolar surgery, etc. There are several risk factors that would prevent the achievement of treatment objectives. The national protocol for deficiency rickets prevention privileges vitamin D2 versus vitamin D3, which creates a medical risk factor compromising oral health in both children and adults. The article provides sufficient arguments in favour of vitamin D3 vs vitamin D2 prescription for prophylactic and treatment purposes. Conclusions: Considering that vitamin D deficiency is currently a global public health problem, it can be proposed to declare vitamin D deficit/deficiency a priority public health problem at the national level. Vitamin D3 should be elective in preventing deficit. Taking into account the multitude of acute and chronic diseases related to vitamin D deficiency, in order to improve the status of vitamin D in all population categories, it is necessary to include vitamin D3 in the list of molecules fully subsidized by the state and distributed free of charge at least to children under the age of 5 years and adolescents in the period of intensive growth.

1 January 2025 in Case Reports in Pediatrics
Verified
Journal Article
Open access
Berthold BIVIGOU MBOUMBABerthold BIVIGOU MBOUMBA
Berthold BIVIGOU MBOUMBA
CZC. Eyi Zang
C. Eyi Zang
PBPamela Moussavou Boundzanga
Pamela Moussavou Boundzanga
YLY. Loumouamou
Y. Loumouamou
JSJ. F. Djoba Siawaya
J. F. Djoba Siawaya
SAS. Ategbo
S. Ategbo
Introduction: Early antiretroviral therapy has a positive impact on the follow‐up of an HIV‐positive child, allowing assessment of the child’s clinical and biological course. We report two cases to highlight the effects of early triple antiretroviral therapy (cART) on viral remission with seroreversion of HIV‐infected infants in Gabon. Case Presentation: We present two cases of infants born to HIV‐infected mothers in Libreville (Gabon). The first infant was referred to the “Center Hospitalier Universitaire Mère‐Enfant” (CHUME FJE) with a positive PCR result. He was born to a mother living with HIV, whose adherence to ART had been intermittent (7th and 9th months of pregnancy). Delivery was vaginal. At birth, nevirapine was administered discontinuously for 6 weeks. After a positive GenXpert PCR at 7 weeks, triple therapy was started with abacavir–lamivudine and ritonavir‐boosted lopinavir (2IN‐1IP). At 2 months, he was asymptomatic, and his clinical and laboratory parameters were normal. A second PCR at another Level 3 reference laboratory (CIRMF) confirmed HIV infection. We switched the antiprotease with an anti‐integrase (dolutegravir, which was available). After 9 months of treatment, the patient’s nutritional status was considered satisfactory, and the DNA PCR performed on GenXpert was negative. The second infant born to a mother living with HIV was admitted for posthospital monitoring of perinatal asphyxia. He was born by caesarean section, and nevirapine had been administered from birth. He was put on ART after two positive PCRs with zidovudine–lamivudine –nevirapine. At 4 months, the GenXpert DNA PCR became negative. Conclusion: Virological remission with seroreversion of a previously HIV‐infected infant is possible in Gabon. Further immunological (Ac assay) and virological (ultrasensitive proviral DNA on blood mononuclear cells) tests are needed in this infant to determine his definitive status.